Can Lab-Grown brain cells replace what Parkinson's destroys?

NCT ID NCT06482268

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This early-stage trial tests whether transplanting lab-grown dopamine-producing cells into the brains of people with Parkinson's disease is safe and might help replace the cells lost to the disease. About 7 adults with Parkinson's who have not responded well to standard medications will receive the cell transplant. The study will monitor for side effects and check whether the cells survive and improve symptoms over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Human induced pluripotent stem cell-derived dopaminergic progenitors (CT1-DAP001)
What this could lead to
If successful, this could pave the way for a one-time cell replacement therapy that restores lost dopamine neurons, potentially reducing or eliminating the need for daily Parkinson's medications.
What could go wrong
This is an early, small trial focused on safety. The transplanted cells may not integrate properly, could cause unwanted growth or side effects, and any benefit may be limited or temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PD - PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, San Diego

    RECRUITING

    La Jolla, California, 92037, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.